The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
20 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,603,998 in first-year total cost, median $213,241.
Most frequent study sections
- Special Emphasis Panel[ZRG1 OTC-M (08)]5
- Cancer Prevention Study Section[CPSS]4
- Special Emphasis Panel[ZRG1 OTC-D (08)]2
- Cancer Immunopathology and Immunotherapy Study Section[CII]1
- Developmental Therapeutics Study Section[DT]1
Most frequent institutions
- BECKMAN RESEARCH INSTITUTE/CITY OF HOPE2
- UNIVERSITY OF FLORIDA2
- ARIZONA STATE UNIVERSITY-TEMPE CAMPUS1
- CLEVELAND CLINIC LERNER COM-CWRU1
- DUKE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2023 | Deciphering microbial contribution to androgen bioavailability in castration resistant prostate cancer patients1R21CA277064-01 | GHARAIBEH, RAADJOBIN, CHRISTIAN | UNIVERSITY OF FLORIDA, FL | $207,931 | CPSS |
| 2022 | Designer EcN for treatment of solid tumors1R21CA249995-01A1 | LESSER, CAMMIE | MASSACHUSETTS GENERAL HOSPITAL, MA | $249,442 | ZRG1 |
| 2022 | Utilizing Hybrid Antigen-Presenting Neutrophils to Prime WT1-Specific Immune Responses as Therapy for Acute Leukemia1R21CA256593-01A1 | MANUEL, EDWIN | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $246,840 | ZRG1 |
| 2022 | Repurposing Mycobacterium tuberculosis tRNase toxins for cancer chemotherapy1R21CA267852-01 | WOYCHIK, NANCY ANN | RBHS-ROBERT WOOD JOHNSON MEDICAL SCHOOL, NJ | $236,333 | DMP |
| 2022 | Microbiome-derived regulators of therapy-resistant colorectal tumors1R21CA267707-01 | GRIFFIN, TIMOTHY J.JAGTAP, PRATIK DSUBRAMANIAN, SUBBAYA | UNIVERSITY OF MINNESOTA, MN | $218,550 | MCT2 |
| 2022 | Engineering non-proliferating-but-active (NPBA) probiotic for breast-cancer gene therapy1R21CA267427-01 | HOVEY, RUSSELL CTAN, CHEEMENG | UNIVERSITY OF CALIFORNIA AT DAVIS, CA | $206,627 | DT |
| 2022 | Chemical Remodeling of Cell Surface to Enhance the Accumulation of Therapeutic Bacteria to Tumors1R21CA259800-01A1 | PIRES, MARCOS M.THEVENIN, DAMIEN | UNIVERSITY OF VIRGINIA, VA | $197,477 | ZRG1 |
| 2022 | Cancer-specific metabolites as cues to engineer and target anti-tumor therapeutic bacteria1R21CA267711-01A1 | DWIDAR, MOHAMMED | CLEVELAND CLINIC LERNER COM-CWRU, OH | $188,169 | CPSS |
| 2022 | Bacteriophage-mediated microbiota modification to prevent colorectal cancer development1R21CA264927-01A1 | EL HADDAD, LYNNJOBIN, CHRISTIAN | UNIVERSITY OF FLORIDA, FL | $178,234 | CPSS |
| 2022 | Validating p53 Ser46 crotonylation as a potential target for possible anti-cancer therapy1R21CA272890-01 | LU, HUA | TULANE UNIVERSITY OF LOUISIANA, LA | $177,650 | MONC |
| 2022 | Mechanisms of anti-tumor activity of group A Streptococcus in pancreatic adenocarcinoma1R21CA267302-01A1 | BOONE, BRIAN ALUKOMSKI, SLAWOMIR | WEST VIRGINIA UNIVERSITY, WV | $177,650 | ZRG1 |
| 2021 | Transplanting Unique Human Microbiomes to Improve Immunotherapy in Glioblastoma1R21CA252634-01A1 | EGAN, KATHLEEN M.MCFARLAND, BRADEN COX | UNIVERSITY OF ALABAMA AT BIRMINGHAM, AL | $415,031 | ZRG1 |
| 2021 | African trypanosome parasites: a new tool to unveil potential immunological strategies to target CLL1R21CA259345-01 | DE TREZ, CARLHU, CHIH-CHI ANDREW | METHODIST HOSPITAL RESEARCH INSTITUTE, TX | $360,852 | IHD |
| 2021 | Multi-strain, live biotherapeutics as adjuncts to checkpoint inhibitor therapy1R21CA249822-01A1 | KIM, HYUNGSOORAMER-TAIT, AMANDA ELLEN | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $263,086 | ZRG1 |
| 2021 | Effects of tumor-microbial interactions on EGFR-targeted therapy resistance in lung cancer1R21CA263751-01 | RAZ, DAN J | BECKMAN RESEARCH INSTITUTE/CITY OF HOPE, CA | $246,840 | MCT1 |
| 2021 | Elucidating the role of intratumoral microbiota on immunotherapy efficacy1R21CA248904-01A1 | REDMOND, WILLIAM L | PROVIDENCE PORTLAND MEDICAL CENTER, OR | $234,218 | CPSS |
| 2021 | Cancer therapy with a combination of oncolytic bacteria and virus to enhance targeted cell killing and anti-tumor immune responses1R21CA249517-01A1 | KONG, WEIRAHMAN, MASMUDUR MOHAMMED | ARIZONA STATE UNIVERSITY-TEMPE CAMPUS, AZ | $220,193 | ZRG1 |
| 2021 | Remotely controlled listerial bactodrones for cancer immunotherapy1R21CA249814-01A1 | GIGLEY, JASONGOMELSKY, MARK | UNIVERSITY OF WYOMING, WY | $186,018 | ZRG1 |
| 2020 | Novel immunotherapeutic regimen combining the dendritic cell expansion power of Albumin-Flt3L and inflammatory cues of Salmonella1R21DE029910-01 | HUNG, CHIEN-FU | JOHNS HOPKINS UNIVERSITY, MD | $204,688 | CII |
| 2020 | The impact of genetic diversity among Akkermansia strains on the effectivenes of immune checkpoint inhibitors in cancer immunotherapies1R21CA249243-01 | HE, YOU-WENVALDIVIA, RAPHAEL HZHANG, TIAN | DUKE UNIVERSITY, NC | $188,169 | ZRG1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.